Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index of 19-29kg/m2, inclusive~* Weight of 50-95kg, inclusive~* Clinically normal physical findings and laboratory values including hepatitis B, hepatitis C, and HIV, as judged by the Investigator~Exclusion Criteria:~* Significant clinical illness within the 2 weeks preceding the first dose of investigational products, as judged by the Investigator~* History of mental, cardiac, renal, hepatitis, neurological, or significant gastrointestinal disease, as judged by the Investigator~* Condition which could modify the absorption of the investigational products, as judged by the Investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): combination capsule of Esomeprazole 40mg + ASA 325mg
- 2 (Type: EXPERIMENTAL): Esomeprazole 40 mg capsule and ASA 325 mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).